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Persistent Pulmonary Hypertension of the newborn
(PPHN) is the clinical syndrome that is characterized by
the failure to achieve or sustain pulmonary vasodilation at
birth, leading to severe hypoxemia due to extrapulmonary
right-to-left shunting of blood across the foramen ovale
and ductus arteriosus. As a potent and selective pulmo-
nary vasodilator, inhaled NO (iNO) has been shown to be
an effective therapy for PPHN. However, some infants
have limited or no response to iNO therapy, leading to the
need for ECMO therapy or death. Mechanisms that con-
tribute to poor responses to iNO in some infants with
PPHN are incompletely understood, but are partly related
to impairment of NO-cGMP signalling in the hypertensive
neonatal pulmonary circulation. Based on past studies
that demonstrated impaired production of endogenous
nitric oxide (NO) in PPHN, we hypothesized that BAY 41-
2272, a direct soluble guanylate cyclase (sGC) activator,
may be a potent pulmonary vasodilator in the perinatal
pulmonary circulation, thereby providing a novel treat-
ment strategy for severe PPHN.
To test this hypothesis, we performed a series of experi-
ments in chronically–prepared, late gestation fetal sheep
(between 128 – 135 days; term = 147 days). At surgery,
catheters were placed in the main pulmonary artery
(MPA), aorta (Ao), and left atrium to measure pressures,
and a flow transducer was placed on the left pulmonary
artery (LPA) to measure blood flow. An additional cathe-
ter was placed in the LPA for selective intrapulmonary
drug infusion. After at least 2 days recovery from surgery,
we infused BAY 41-2272 (0.1 – 2.5 mg x 10 min) into the
LPA. We found that BAY 41-2272 caused a very potent (up
to 5-fold) increase in pulmonary blood flow and fall in
PVR. During prolonged (2 hr) infusions, BAY 41-2272-
induced vasodilation was sustained throughout the study
period. Pretreatment with nitro-L-arginine, a NOS inhibi-
tor, did not attenuate pulmonary vasodilation. When
compared with sildenafil, a cGMP-specific type 5 phos-
phodiesterase (PDE5) inhibitor, the fetal pulmonary
vasodilator response to BAY 41-2272 was more pro-
longed.
To determine the effects of BAY 41-2272 in a model of
severe PPHN, we performed similar experiments in chron-
ically instrumented fetal sheep after ligation of the ductus
arteriosus (DA) ("experimental PPHN"). In this model,
DA ligation causes progressive increases in PAP and PVR
over several days, which remain elevated even during ven-
tilation with hyperoxia after birth. In this model, we com-
pared the pulmonary vascular effects of BAY 41-2272,
acetylcholine (an endothelium–dependent agonist), and
sildenafil. Despite the early loss of acetylcholine-induced
vasodilation, BAY 41-2272 and sildenafil continued to
cause potent fetal pulmonary vasodilation. After 9 days of
intrauterine pulmonary hypertension, sheep were deliv-
ered, intubated and ventilated with supplemental oxygen.
At birth, BAY 41-2272 dramatically reduced PVR and aug-
mented the vasodilator response to iNO. Sildenafil also
caused pulmonary vasodilation and enhanced the
response to inhaled NO. We conclude that BAY 41-2272
causes potent pulmonary vasodilation in normal sheep
and in an experimental model of severe PPHN, and that
these effects were at least as potent as sildenafil. In addi-
tion, BAY 41-2272 enhances iNO-induced pulmonary
vasodilation in experimental PPHN after birth. We specu-
late that BAY 41-2272 may provide a novel treatment
strategy for severe PPHN, especially in newborns with par-
tial or poor responses to inhaled NO therapy.
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